Cytek Biosciences (CTKB)
(Delayed Data from NSDQ)
$5.09 USD
-0.20 (-3.78%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.10 +0.01 (0.20%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Cash flow Statements
Fiscal Year End for Cytek Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -12.15 | 2.48 | 3.03 | 19.41 | NA |
Depreciation/Amortization & Depletion | 9.23 | 5.66 | 1.24 | 0.60 | NA |
Net Change from Assets/Liabilities | -10.51 | -39.93 | -8.65 | -7.54 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 18.71 | 19.55 | 9.01 | 2.68 | NA |
Net Cash From Operating Activities | 5.28 | -12.23 | 4.63 | 15.16 | NA |
Property & Equipment | -4.65 | -9.75 | -4.36 | -1.55 | NA |
Acquisition/ Disposition of Subsidiaries | -44.90 | 0.00 | -17.00 | 0.00 | NA |
Investments | -44.17 | -46.04 | 0.37 | 0.00 | NA |
Other Investing Activities | -0.18 | -0.12 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | -93.89 | -55.91 | -20.99 | -1.55 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -40.83 | 2.79 | 216.33 | 119.84 | NA |
Issuance (Repayment) of Debt | -0.57 | 2.93 | -2.77 | 2.77 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -0.42 | -0.21 | 0.00 | 0.00 | NA |
Net Cash from Financing Activities | -41.81 | 5.51 | 213.56 | 122.61 | NA |
Effect of Exchange Rate Changes | -1.45 | -2.49 | 1.30 | -0.59 | NA |
Net Change In Cash & Equivalents | -131.87 | -65.12 | 198.50 | 135.63 | NA |
Cash at Beginning of Period | 299.50 | 364.62 | 166.12 | 30.49 | NA |
Cash at End of Period | 167.63 | 299.50 | 364.62 | 166.12 | NA |
Diluted Net EPS | -0.09 | 0.02 | 0.00 | NA | NA |
Fiscal Year End for Cytek Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -16.60 | -6.17 | -12.15 | -17.65 | -11.20 |
Depreciation/Amortization & Depletion | 4.94 | 2.46 | 9.23 | 6.81 | 4.25 |
Net Change from Assets/Liabilities | 9.95 | 1.85 | -10.51 | -6.67 | -1.40 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 11.87 | 5.82 | 18.71 | 13.29 | 8.36 |
Net Cash From Operating Activities | 10.16 | 3.96 | 5.28 | -4.23 | 0.01 |
Property & Equipment | -1.54 | -0.57 | -4.65 | -3.15 | -1.82 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -44.90 | -44.90 | -44.90 |
Investments | -1.99 | -5.13 | -44.17 | -74.80 | -119.32 |
Other Investing Activities | -0.20 | -0.06 | -0.18 | -0.12 | -0.06 |
Net Cash from Investing Activities | -3.73 | -5.75 | -93.89 | -122.96 | -166.08 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -0.93 | 0.51 | -40.83 | -7.32 | 0.67 |
Issuance (Repayment) of Debt | -0.28 | -0.14 | -0.57 | -0.43 | -0.29 |
Increase (Decrease) Short-Term Debt | 1.39 | 1.39 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.28 | -0.15 | -0.42 | -0.32 | -0.17 |
Net Cash from Financing Activities | -0.10 | 1.61 | -41.81 | -8.06 | 0.22 |
Effect of Exchange Rate Changes | 3.96 | 1.70 | -1.45 | -0.62 | -2.10 |
Net Change In Cash & Equivalents | 10.29 | 1.51 | -131.87 | -135.87 | -167.96 |
Cash at Beginning of Period | 167.63 | 167.63 | 299.50 | 299.50 | 299.50 |
Cash at End of Period | 177.92 | 169.14 | 167.63 | 163.63 | 131.54 |
Diluted Net EPS | -0.08 | -0.05 | 0.04 | -0.05 | -0.03 |